Stay updated with breaking news from Partial Hematologic Recovery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LEXINGTON - Curis, Inc., , a biotechnology company focused on the development of emavusertib, an orally available small molecule triple target inhibitor for the treatment of hematologic...
/PRNewswire/ -- Curis, Inc., (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule triple...
Curis, Inc. announced that the U.S. Food and Drug Administration has removed the partial clinical hold on the TakeAim Leukemia Phase 1/2 study of emavusertib. Further, the recommended phase 2 dose ...